Certified by Founder Lodge
Myricx Bio
United Kingdom - London
START UP
1 Disclosed Funding Rounds $115,246,800
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 09 ,2024 | Series A | $115,246,800 |
Novo Holdings
British Patient Capital
Abingworth
Brandon Capital
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
